VIA Pharmaceuticals (VIA Pharmaceuticals) ROCE % : 0.00% (As of Dec. 2010)

View and export this data going back to 1998. Start your Free Trial

What is VIA Pharmaceuticals ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. VIA Pharmaceuticals's annualized ROCE % for the quarter that ended in Dec. 2010 was 0.00%.

VIA Pharmaceuticals ROCE % Historical Data

The historical data trend for VIA Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VIA Pharmaceuticals ROCE % Chart

VIA Pharmaceuticals Annual Data

Trend

Dec01

Dec02

Dec03

Dec04

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

ROCE %

Get a 7-Day Free Trial

-76.39

-252.23

-184.74

VIA Pharmaceuticals Quarterly Data
	Mar06	Jun06	Sep06	Dec06	Mar07	Jun07	Sep07	Dec07	Mar08	Jun08	Sep08	Dec08	Mar09	Jun09	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10
ROCE %	Get a 7-Day Free Trial															-	-	-	-	-

VIA Pharmaceuticals ROCE % Calculation

VIA Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Dec. 2010 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2010 )		(A: Dec. 2009 )		(A: Dec. 2010 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2010 )		(A: Dec. 2009 )		(A: Dec. 2010 )
	=	-5.914	/	( ( (2.556 - 13.717)	+	(0.5 - 18.989) )	/ 2 )
	=	-5.914	/	( (-11.161	+	-18.489)	/ 2 )
	=	-5.914	/	-14.825
	=	39.89 %

VIA Pharmaceuticals's ROCE % of for the quarter that ended in Dec. 2010 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2010 )		(Q: Sep. 2010 )		(Q: Dec. 2010 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2010 )		(Q: Sep. 2010 )		(Q: Dec. 2010 )
	=	-3.54	/	( ( (0.49 - 17.103)	+	(0.5 - 18.989) )	/ 2 )
	=	-3.54	/	( ( -16.613	+	-18.489 )	/ 2 )
	=	-3.54	/	-17.551
	=	0 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2010) EBIT data.

VIA Pharmaceuticals (GREY:VIAP) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

VIA Pharmaceuticals ROCE % Related Terms

Thank you for viewing the detailed overview of VIA Pharmaceuticals's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

VIA Pharmaceuticals (VIA Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VIA Pharmaceuticals Inc (GREY:VIAP) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

750 Battery Street, Suite 330, San Francisco, CA, USA, 94111

Website

http://www.baycitycapital.com

VIA Pharmaceuticals Inc is a development stage biotechnology company focuses on the development of small-molecule drugs to treat cardiovascular and metabolic diseases.

Executives

Fred B Craves	director	750 BATTERY ST, STE 600, SAN FRANCISCO CA 94111
Bay City Capital Fund Iv, L.p.	10 percent owner	750 BATTERY STREET, SUITE 400, SAN FRANCISCO CA 94111
Bay City Capital Management Iv Llc	10 percent owner	750 BATTERY STREET, SUITE 400, SAN FRANCISCO CA 94111
Bay City Capital Fund Iv Co Invesment Fund Lp	10 percent owner	750 BATTERY ST STE 400, SAN FRANCISCO CA 94111
Bay City Capital Llc	10 percent owner	750 BATTERY STREET STE 400, SAN FRANCISCO CA 94111
Douglas B Given	director	C/O NEORX CORP, 410 WEST HARRISON ST, SEATTLE WA 98119
Karen Steil Wright	officer: V.P. ? Finance, Controller	750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Lawrence Kenneth Cohen	director, officer: CEO and President	750 BATTERY STREET, SUITE 330 SAN FRANCISCO CA 94111
Richard L Anderson	director	14031 216TH WAY NE, WOODINVILLE WA 98072
Mark Bagnall	director	3876 BAY CENTER PLACE, HAYWARD CA 94545
Rebecca Taub	officer: SVP, Research & Development	750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Adeoye Y Olukotun	officer: Chief Medical Officer	3621 SOUTH STATE ST, 695 KMS PL, ANN ARBOR MI 48108
Deerfield Special Situations Fund International Ltd	10 percent owner, other: Possible Member of 10% Group	BISON COURT, ROAD TOWN, TORTOLA D8 -
Deerfield Special Situations Fund, L.p.	10 percent owner, other: Possible Member of 10% Group	780 3RD AVENUE, 37TH FLOOR, NEW YORK NY 10017
James E Flynn	10 percent owner, other: Possible Member of 10% Group	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017

VIA Pharmaceuticals (VIA Pharmaceuticals) Headlines

From GuruFocus

VIA Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 11-12-2009

VIA Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus • 08-12-2009